PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment

Papers of special note have been highlighted as: • of interest

References

• 1 Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, immunity, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 17(1), 615–675 (2001).Crossref, Medline, CAS, Google Scholar
• 2 Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7(8), 606–619 (2006).Crossref, Medline, CAS, Google Scholar
• 3 Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer 5(12), 921–929 (2005).Crossref, Medline, CAS, Google Scholar
• 4 Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl Acad. Sci. USA 96(8), 4240–4245 (1999).Crossref, Medline, CAS, Google Scholar
• 5 Samuels Y. High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670), 554 (2004).Crossref, Medline, CAS, Google Scholar
• 6 Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6(3), 184–192 (2006).Crossref, Medline, CAS, Google Scholar
• 7 Hu L, Hofmann J, Jaffe RB. Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma. Clin. Cancer Res. 11(22), 8208–8212 (2005).Crossref, Medline, CAS, Google Scholar
• 8 Jiang BH, Zheng JZ, Aoki M, Vogt PK. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc. Natl Acad. Sci. USA 97(4), 1749–1753 (2000).Crossref, Medline, CAS, Google Scholar
• 9 Chen J-S, Wang Q, Fu X-H et al. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol. Res. 39(2), 177–186 (2009).Crossref, Medline, CAS, Google Scholar
• 10 de Sousa Mesquita AP, de Araújo Lopes S, Pernambuco Filho PCA, Nader HB, Lopes CC. Acquisition of anoikis resistance promotes alterations in the Ras/ERK and PI3K/Akt signaling pathways and matrix remodeling in endothelial cells. Apoptosis 22(9), 1116–1137 (2017).Crossref, Medline, Google Scholar
• 11 Zebedin E, Simma O, Schuster C et al. Leukemic challenge unmasks a requirement for PI3K{delta} in NK cell-mediated tumor surveillance. Blood 112(12), 4655–4664 (2008).Crossref, Medline, CAS, Google Scholar
• 12 Putz EM, Prchal-Murphy M, Simma OA et al. PI3Kδ is essential for tumor clearance mediated by cytotoxic T lymphocytes. PLoS ONE 7(7), e40852 (2012).Crossref, Medline, CAS, Google Scholar
• 13 Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem. Sci. 30(4), 194–204 (2005).Crossref, Medline, CAS, Google Scholar
• 14 Fritsch R, Downward J. SnapShot: class I PI3K isoform signaling. Cell 154(4), 940–940.e1 (2013).Crossref, Medline, CAS, Google Scholar
• 15 Mellor P, Furber LA, Nyarko JNK, Anderson DH. Multiple roles for the p85α isoform in the regulation and function of PI3K signalling and receptor trafficking. Biochem. J. 441(1), 23–37 (2011).Crossref, Google Scholar
• 16 Walker EH, Perisic O, Ried C, Stephens L, Williams RL. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 402(6759), 313–320 (1999).Crossref, Medline, CAS, Google Scholar
• 17 Rommel C, Camps M, Ji H. PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat. Rev. Immunol. 7(3), 191–201 (2007).Crossref, Medline, CAS, Google Scholar
• 18 Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene 27(41), 5486–5496 (2008).Crossref, Medline, CAS, Google Scholar
• 19 Yu J, Zhang Y, McIlroy J, Rordorf-Nikolic T, Orr GA, Backer JM. Regulation of the p85/p110 phosphatidylinositol 3′-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol. Cell. Biol. 18(3), 1379–1387 (1998).Crossref, Medline, CAS, Google Scholar
• 20 Luo J, Field SJ, Lee JY, Engelman JA, Cantley LC. The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. J. Cell Biol. 170(3), 455–464 (2005).Crossref, Medline, CAS, Google Scholar
• 21 Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11(5), 329–341 (2010).Crossref, Medline, CAS, Google Scholar
• 22 Pawson T. Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell 116(2), 191–203 (2004).Crossref, Medline, CAS, Google Scholar
• 23 Domchek SM, Chatterjee S, Shoelson SE, Auger KR, Burke TR. Inhibition of SH2 domain/phosphoprotein association by a nonhydrolyzable phosphonopeptide. Biochemistry 31(41), 9865–9870 (1992).Crossref, Medline, CAS, Google Scholar
• 24 Rodriguez-Viciana P, Warne PH, Dhand R et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370(6490), 527–532 (1994).Crossref, Medline, CAS, Google Scholar
• 25 Gupta S, Ramjaun AR, Haiko P et al. Binding of Ras to phosphoinositide 3-kinase p110α is required for Ras-driven tumorigenesis in mice. Cell 129(5), 957–968 (2007).Crossref, Medline, CAS, Google Scholar
• 26 McLendon R, Friedman A, Bigner D et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216), 1061–1068 (2008).Crossref, Medline, CAS, Google Scholar
• 27 Broderick DK, Di C, Parrett TJ et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res. 64(15), 5048–5050 (2004).Crossref, Medline, CAS, Google Scholar
• 28 TCGA Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517(7536), 576–582 (2015).Crossref, Medline, Google Scholar
• 29 Qiu W, Schönleben F, Li X et al. PIK3CA mutations in head and neck squamous cell carcinoma. Clin. Cancer Res. 12(5), 1441–1446 (2006).Crossref, Medline, CAS, Google Scholar
• 30 Murugan AK, Thi Hong N, Fukui Y, Munirajan AK, Tsuchida N. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. Int. J. Oncol. 32(1), 101–111 (2008).Medline, CAS, Google Scholar
• 31 Firoozinia M, Jahromi MZ, Moghadamtousi SZ, Nikzad S, Kadir HA. PIK3CA gene amplification and PI3K p110α protein expression in breast carcinoma. Int. J. Med. Sci. 11(6), 620–625 (2014).Crossref, Medline, Google Scholar
• 32 Yip WK, He PY, Abdullah MA, Yusoff S, Seow HF. Increased expression of phosphatidylinositol 3-kinase p110α and gene amplification of PIK3CA in nasopharyngeal carcinoma. Pathol. Oncol. Res. 22(2), 413–419 (2016).Crossref, Medline, CAS, Google Scholar
• 33 Levine DA. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin. Cancer Res. 11(8), 2875–2878 (2005).Crossref, Medline, CAS, Google Scholar
• 34 Wu G, Xing M, Mambo E et al. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res. 7(5), R609–R616 (2005).Crossref, Medline, CAS, Google Scholar
• 35 Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110 of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl Acad. Sci. USA 105(7), 2652–2657 (2008).Crossref, Medline, CAS, Google Scholar
• 36 Ikenoue T, Kanai F, Hikiba Y et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 65(11), 4562–4567 (2005).Crossref, Medline, CAS, Google Scholar
• 37 Gymnopoulos M, Elsliger M-A, Vogt PK. Rare cancer-specific mutations in PIK3CA show gain of function. Proc. Natl Acad. Sci. USA 104(13), 5569–5574 (2007).Crossref, Medline, CAS, Google Scholar
• 38 Philp AJ, Campbell IG, Leet C et al. The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res. 61(20), 7426–7429 (2001).Medline, CAS, Google Scholar
• 39 Cheung LWT, Hennessy BT, Li J et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 1(2), 170–185 (2011).Crossref, Medline, CAS, Google Scholar
• 40 Jaiswal BS, Janakiraman V, Kljavin NM et al. Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell 16(6), 463–474 (2009).Crossref, Medline, CAS, Google Scholar
• 41 Cizkova M, Vacher S, Meseure D et al. PIK3R1 underexpression is an independent prognostic marker in breast cancer. BMC Cancer 13, 545 (2013).Crossref, Medline, Google Scholar
• 42 Taniguchi CM, Winnay J, Kondo T et al. The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling. Cancer Res. 70(13), 5305–5315 (2010).Crossref, Medline, CAS, Google Scholar
• 43 Luo J, Sobkiw CL, Logsdon NM et al. Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/− mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proc. Natl Acad. Sci. USA 102(29), 10238–43 (2005).Crossref, Medline, CAS, Google Scholar
• 44 Luo J, Cantley LC. The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer. Cell Cycle 4(10), 1309–1312 (2005).Crossref, Medline, CAS, Google Scholar
• 45 Cortés I, Sánchez-Ruíz J, Zuluaga S et al. p85β phosphoinositide 3-kinase subunit regulates tumor progression. Proc. Natl Acad. Sci. USA 109(28), 11318–11323 (2012).Crossref, Medline, CAS, Google Scholar
• 46 Knobbe CB, Reifenberger G. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3′-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol. 13, 507–518 (2003).Crossref, Medline, CAS, Google Scholar
• 47 Rao SK, Edwards J, Joshi AD, Siu IM, Riggins GJ. A survey of glioblastoma genomic amplifications and deletions. J. Neurooncol. 96(2), 169–179 (2010).Crossref, Medline, CAS, Google Scholar
• 48 Liu P, Morrison C, Wang L et al. Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis 33(7), 1270–1276 (2012).Crossref, Medline, Google Scholar
• 49 Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21(3), 309–322 (2012).Crossref, Medline, CAS, Google Scholar
• 50 Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12(4), 298–306 (2012).Crossref, Medline, CAS, Google Scholar
• 51 Sasaki T, Irie-Sasaki J, Jones RG et al. Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration. Science 287(5455) 1040–1046 (2000).Crossref, Medline, CAS, Google Scholar
• 52 Zhong H, Chiles K, Feldser D et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60(6), 1541–1545 (2000).Medline, CAS, Google Scholar
• 53 Mazure NM, Chen EY, Laderoute KR, Giaccia AJ. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90(9), 3322–3331 (1997).Crossref, Medline, CAS, Google Scholar
• 54 Xia C, Meng Q, Cao Z, Shi X, Jiang BH. Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression. J. Cell. Physiol. 209(1), 56–66 (2006).Crossref, Medline, CAS, Google Scholar
• 55 Fang J, Ding M, Yang L, Liu L-Z, Jiang B-H. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell. Signal. 19(12), 2487–2497 (2007).Crossref, Medline, CAS, Google Scholar
• 56 Gerber HP, McMurtrey A, Kowalski J et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273, 30336–30343 (1998).Crossref, Medline, CAS, Google Scholar
• 57 Guo D, Jia Q, Song HY, Warren RS, Donner DB. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J. Biol. Chem. 270(12), 6729–33 (1995).Crossref, Medline, CAS, Google Scholar
• 58 Yuan TL, Choi HS, Matsui A et al. Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proc. Natl Acad. Sci. USA 105(28), 9739–9744 (2008).Crossref, Medline, CAS, Google Scholar
• 59 Schnell CR, Stauffer F, Allegrini PR et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res. 68(16), 6598–6607 (2008).Crossref, Medline, CAS, Google Scholar
• 60 Graupera M, Guillermet-Guibert J, Foukas LC et al. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 453(7195), 662–666 (2008).Crossref, Medline, CAS, Google Scholar
• 61 Heller R, Chang Q, Ehrlich G et al. Overlapping and distinct roles for PI3Kbeta and gamma isoforms in S1P-induced migration of human and mouse endothelial cells. Cardiovasc. Res. 80(1), 96–105 (2008).Crossref, Medline, CAS, Google Scholar
• 62 Yoshioka K, Yoshida K, Cui H et al. Endothelial PI3K-C2alpha, a class II PI3K, has an essential role in angiogenesis and vascular barrier function. Nat. Med. 18(10), 1560–1569 (2012).Crossref, Medline, CAS, Google Scholar
• 63 Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med. 17(11), 1359–1370 (2011).Crossref, Medline, CAS, Google Scholar
• 64 Schmid MC, Avraamides CJ, Dippold HC et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression. Cancer Cell. 19(6), 715–727 (2011).Crossref, Medline, CAS, Google Scholar
• 65 Chavakis E, Carmona G, Urbich C et al. Phosphatidylinositol-3-kinase-γ is integral to homing functions of progenitor cells. Circ. Res. 102(8), 942–949 (2008).Crossref, Medline, CAS, Google Scholar
• 66 Madeddu P, Kraenkel N, Barcelos LS et al. Phosphoinositide 3-kinase gamma gene knockout impairs postischemic neovascularization and endothelial progenitor cell functions. Arterioscler. Thromb. Vasc. Biol. 28(1), 68–76 (2008).Crossref, Medline, CAS, Google Scholar
• 67 Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J. Cell Sci. 123(24), 4195–4200 (2010).Crossref, Medline, CAS, Google Scholar
• 68 Lu P, Takai K, Weaver VM, Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb. Perspect. Biol. 3(12), pii:a005058 (2011).Crossref, Google Scholar
• 69 Xing F, Saidou J, Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front. Biosci. (Landmark Ed.) 15(2), 166–179 (2010).Crossref, Medline, CAS, Google Scholar
• 70 Bhowmick NA. TGF-signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303(5659), 848–851 (2004).Crossref, Medline, CAS, Google Scholar
• 71 Wu X, Chen X, Zhou Q et al. Hepatocyte growth factor activates tumor stromal fibroblasts to promote tumorigenesis in gastric cancer. Cancer Lett. 335(1), 128–135 (2013).Crossref, Medline, CAS, Google Scholar
• 72 Elenbaas B, Weinberg RA. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp. Cell Res. 264(1), 169–184 (2001).Crossref, Medline, CAS, Google Scholar
• 73 Chen X-C, Wei X-T, Guan J-H, Shu H, Chen D. EGF stimulates glioblastoma metastasis by induction of matrix metalloproteinase-9 in an EGFR-dependent mechanism. Oncotarget 8(39), 65969–65982 (2017).Crossref, Medline, Google Scholar
• 74 Ding P, Zhang X, Jin S et al. CD147 functions as the signaling receptor for extracellular divalent copper in hepatocellular carcinoma cells. Oncotarget 8(31), 51151–51163 (2017).Crossref, Medline, Google Scholar
• 75 Zhou R, Xu L, Ye M, Liao M, Du H, Chen H. Formononetin inhibits migration and invasion of MDA-MB-231 and 4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through PI3K/AKT signaling pathways. Horm. Metab. Res. 46(11), 753–760 (2014).Crossref, Medline, CAS, Google Scholar
• 76 Kuang W, Deng Q, Deng C, Li W, Shu S, Zhou M. Hepatocyte growth factor induces breast cancer cell invasion via the PI3K/Akt and p38 MAPK signaling pathways to up-regulate the expression of COX2. Am. J. Transl. Res. 9(8), 3816–3826 (2017).Medline, CAS, Google Scholar
• 77 Martin AL, Schwartz MD, Jameson SC, Shimizu Y. Selective regulation of CD8 effector T cell migration by the p110γ isoform of phosphatidylinositol 3-kinase. J. Immunol. 180(4), 2081–2088 (2008).Crossref, Medline, CAS, Google Scholar
• 78 Fortin CF, Cloutier A, Ear T et al. A class IA PI3K controls inflammatory cytokine production in human neutrophils. Eur. J. Immunol. 41(6), 1709–1719 (2011).Crossref, Medline, CAS, Google Scholar
• 79 Thomas MS, Mitchell JS, DeNucci CC, Martin AL, Shimizu Y. The p110gamma isoform of phosphatidylinositol 3-kinase regulates migration of effector CD4 T lymphocytes into peripheral inflammatory sites. J. Leukoc. Biol. 84(3), 814–23 (2008).Crossref, Medline, CAS, Google Scholar
• 80 Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419(6908), 734–738 (2002).Crossref, Medline, CAS, Google Scholar
• 81 Salih HR, Antropius H, Gieseke F et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102(4), 1389–1396 (2003).Crossref, Medline, CAS, Google Scholar
• 82 Boissel N, Rea D, Tieng V et al. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J. Immunol. 176(8), 5108–5116 (2006).Crossref, Medline, CAS, Google Scholar
• 83 Taramelli D, Fossati G, Mazzocchi A, Parmiani G, Delia D, Ferrone S. Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions. Cancer Res. 46(1), 433–439 (1986).Medline, CAS, Google Scholar
• 84 Hemon P, Jean-Louis F, Ramgolam K et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J. Immunol. 186(9), 5173–5183 (2011).Crossref, Medline, CAS, Google Scholar
• 85 Benitez AC, Dai Z, Mann HH et al. Expression, signaling proficiency, and stimulatory function of the NKG2D lymphocyte receptor in human cancer cells. Proc. Natl Acad. Sci. USA 108(10), 4081–4086 (2011).Crossref, Medline, CAS, Google Scholar
• 86 Díaz-Valdés N, Basagoiti M, Dotor J et al. Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFβ1 in melanoma enhances tumor infiltration and immunosuppression. Cancer Res. 71(3), 812–821 (2011).Crossref, Medline, CAS, Google Scholar
• 87 Szajnik M, Czystowska M, Szczepanski MJ, Mandapathil M, Whiteside TL. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS ONE 5(7), e11469 (2010).Crossref, Medline, Google Scholar
• 88 Efimova OV, Kelley TW. Induction of granzyme B expression in T-cell receptor/CD28-stimulated human regulatory T cells is suppressed by inhibitors of the PI3K-mTOR pathway. BMC Immunol. 10, 59 (2009).Crossref, Medline, Google Scholar
• 89 Patton DT, Garden OA, Pearce WP et al. Cutting edge: the phosphoinositide 3-kinase p110 is critical for the function of CD4⁺CD25⁺Foxp3⁺ regulatory T cells. J. Immunol. 177(10), 6598–6602 (2006).Crossref, Medline, CAS, Google Scholar
• 90 Haidinger M, Poglitsch M, Geyeregger R et al. A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. J. Immunol. 185, 3919–3931 (2010).Crossref, Medline, CAS, Google Scholar
• 91 Awasthi A, Samarakoon A, Dai X, Wen R, Wang D, Malarkannan S. Deletion of PI3K-p85alpha gene impairs lineage commitment, terminal maturation, cytokine generation and cytotoxicity of NK cells. Genes Immun. 9(6), 522–535 (2008).Crossref, Medline, CAS, Google Scholar
• 92 Segovis CM, Schoon RA, Dick CJ, Nacusi LP, Leibson PJ, Billadeau DD. PI3K links NKG2D signaling to a CrkL pathway involved in natural killer cell adhesion, polarity, and granule secretion. J. Immunol. 182(11), 6933–6942 (2009).Crossref, Medline, CAS, Google Scholar
• 93 Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu. Rev. Immunol. 31(1), 675–704 (2013). • Comprehensive review of the role of phosphatidylinositol 3-kinase in immune response.Crossref, Medline, CAS, Google Scholar
• 94 Ali K, Soond DR, Piñeiro R et al. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 510(7505), 407–411 (2014).Crossref, Medline, CAS, Google Scholar
• 95 Kaneda MM, Cappello P, Nguyen AV et al. Macrophage PI3Kgamma drives pancreatic ductal adenocarcinoma progression. Cancer Discov. 6(8), 870–885 (2016).Crossref, Medline, CAS, Google Scholar
• 96 Weidner A-S, Panarelli NC, Geyer JT et al. Idelalisib-associated colitis: histologic findings in 14 patients. Am. J. Surg. Pathol. 39(12), 1661–1667 (2015).Crossref, Medline, Google Scholar
• 97 Coutré SE, Barrientos JC, Brown JR et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk. Lymphoma 56(10), 2779–2786 (2015).Crossref, Medline, CAS, Google Scholar